Stay updated on ACP-196 + Pembrolizumab in Hematologic Malignancies Clinical Trial
Sign up to get notified when there's something new on the ACP-196 + Pembrolizumab in Hematologic Malignancies Clinical Trial page.

Latest updates to the ACP-196 + Pembrolizumab in Hematologic Malignancies Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe study record now shows a new document revision (Revision: v3.5.4) and indicates a Redacted CSR Synopsis, with the prior revision (v3.5.3) removed.SummaryDifference0.2%

- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedThis updates the displayed interface/version identifier on the page (revision v3.5.0 → v3.5.3).SummaryDifference0.0%

- Check69 days agoChange DetectedAdded Waldenström macroglobulinemia, Richter syndrome, and B-cell chronic lymphocytic leukemia to the conditions section, and updated site revision from v3.4.3 to v3.5.0.SummaryDifference0.2%

- Check91 days agoChange DetectedThe page now displays revision number v3.4.3, replacing the previous v3.4.2.SummaryDifference0.0%

- Check112 days agoChange DetectedRevision label updated from v3.4.1 to v3.4.2; no other changes to content or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check120 days agoChange Detected- The page revision was updated from v3.4.0 to v3.4.1 (added v3.4.1 and removed v3.4.0).SummaryDifference0.1%

Stay in the know with updates to ACP-196 + Pembrolizumab in Hematologic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ACP-196 + Pembrolizumab in Hematologic Malignancies Clinical Trial page.